NASDAQ: ELTXElicio Therapeutics Inc Stock
$9.25+0.03 (+0.33%)
Updated Apr 24, 2024
ELTX Price
$9.25
Fair Value Price
N/A
Market Cap
$94.68M
52 Week Low
$2.96
52 Week High
$24.39
P/E
-1.33x
P/B
8.32x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$35.20M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.39
Operating Cash Flow
-$33M
Beta
1.37
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ELTX Overview
Angion is a clinical-stage biopharmaceutical company developing small molecule therapeutics to address fibrotic diseases and acute organ injuries. Its lead program is ANG-3070. Angion was founded in 1998 and headquartered in Uniondale, NY.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ELTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ELTX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ELTX is poor value based on its book value relative to its share price (8.32x), compared to the US Biotechnology industry average (5.86x)
P/B vs Industry Valuation
ELTX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ELTX due diligence checks available for Premium users.
Be the first to know about important ELTX news, forecast changes, insider trades & much more!
ELTX News
Valuation
ELTX fair value
Fair Value of ELTX stock based on Discounted Cash Flow (DCF)
Price
$9.25
Fair Value
-$4.18
Undervalued by
321.51%
ELTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ELTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.33x
Industry
15.69x
Market
41.27x
ELTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.32x
Industry
5.86x
ELTX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ELTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.9M
Profit Margin
0%
ELTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$27.1M
Liabilities
$15.8M
Debt to equity
1.39
ELTX's short-term assets ($16.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ELTX's short-term assets ($16.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ELTX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ELTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.9M
Investing
$0.0
Financing
$7.0M
ELTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ELTX vs Biotech Stocks
Elicio Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.